{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:12:18Z","timestamp":1775023938522,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Non-small cell lung cancer (NSCLC) is a common neoplasm with poor prognosis in advanced stages. The clinical work-up in patients with locally advanced NSCLC mostly includes <jats:sup>18<\/jats:sup>F-fluorodeoxyglucose positron emission tomography computed tomography (<jats:sup>18<\/jats:sup>F-FDG PET\/CT) because of its high sensitivity for malignant lesion detection; however, specificity is lower. Diverging results exist whether whole-body MRI (WB-MRI) improves the staging accuracy in advanced lung cancer. Considering WB-MRI being a more time-consuming examination compared to brain MRI, it is important to establish whether or not additional value is found in detecting and characterizing malignant lesions. The purpose of this study is to investigate the value of additional whole-body magnetic resonance imaging, instead of only brain MRI, together with <jats:sup>18<\/jats:sup>F-FDG PET\/CT in staging patients with advanced NSCLC planned for curative treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material and methods<\/jats:title>\n            <jats:p>In a prospective single center study, 28 patients with NSCLC stage 3 or oligometastatic disease were enrolled. In addition to <jats:sup>18<\/jats:sup>F-FDG PET\/CT, they underwent WB-MRI including the thorax, abdomen, spine, pelvis, and contrast-enhanced examination of the brain and liver. <jats:sup>18<\/jats:sup>F-FDG PET\/CT and WB-MRI were separately evaluated by two blinded readers, followed by consensus reading in which the likelihood of malignancy was assessed in detected lesions. Imaging and clinical follow-up for at least 12 months was used as reference standard. Statistical analyses included Fischer\u2019s exact test and Clopped-Pearson.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>28 patients (mean age\u2009\u00b1\u2009SD 70.5\u2009\u00b1\u20098.4 years, 19 women) were enrolled. WB-MRI and FDG-PET\/CT both showed maximum sensitivity and specificity for primary tumor diagnosis and similar sensitivity (<jats:italic>p<\/jats:italic>\u2009=\u20091.00) and specificity (<jats:italic>p<\/jats:italic>\u2009=\u20090.70) for detection of distant metastases. For diagnosis of lymph node metastases, WB-MRI showed lower sensitivity, 0.65 (95% CI: 0.38\u20130.86) than FDG-PET\/CT, 1.00 (95% CI: 0.80-1.00) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), but similar specificity (<jats:italic>p<\/jats:italic>\u2009=\u20090.59).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>WB-MRI in conjunction with <jats:sup>18<\/jats:sup>F-FDG PET\/CT provides no additional value over MRI of the brain only, in staging patients with advanced NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Registered locally and approved by the Uppsala University Hospital committee, registration number ASMR020.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40644-025-00852-6","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T10:12:15Z","timestamp":1741687935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The value of whole-body MRI instead of only brain MRI in addition to 18\u00a0F-FDG PET\/CT in the staging of advanced non-small-cell lung cancer"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3516-3523","authenticated-orcid":false,"given":"Hanna","family":"Holmstrand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lindskog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Sundin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"852_CR1","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3). https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"852_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.arcmed.2020.08.004","volume":"51","author":"DI Suster","year":"2020","unstructured":"Suster DI, Mino-Kenudson M. Molecular pathology of primary Non-small cell lung Cancer. Arch Med Res. 2020;51:8. https:\/\/doi.org\/10.1016\/j.arcmed.2020.08.004.","journal-title":"Arch Med Res"},{"key":"852_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ijms21134569","volume":"21","author":"K Wadowska","year":"2020","unstructured":"Wadowska K, Bil-Lula I, Trembecki \u0141, \u015aliwi\u0144ska-Mosso\u0144 M. Genetic markers in lung cancer diagnosis: A review. Int J Mol Sci. 2020;21:13. https:\/\/doi.org\/10.3390\/ijms21134569.","journal-title":"Int J Mol Sci"},{"key":"852_CR4","doi-asserted-by":"publisher","unstructured":"Rami-Porta R, Goldstraw P. Strength and weakness of the new TNM classification for lung cancer. Eur Respir J. 2010;36(2). https:\/\/doi.org\/10.1183\/09031936.00016210.","DOI":"10.1183\/09031936.00016210"},{"key":"852_CR5","doi-asserted-by":"publisher","unstructured":"Melosky B, Juergens R, McLeod D, et al. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer. 2019;134. https:\/\/doi.org\/10.1016\/j.lungcan.2019.05.027.","DOI":"10.1016\/j.lungcan.2019.05.027"},{"key":"852_CR6","doi-asserted-by":"publisher","unstructured":"Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. (2017) \u2018Radiotherapy for oligometastatic lung cancer\u2019, Frontiers in Oncology, vol. 7, no. SEP. https:\/\/doi.org\/10.3389\/fonc.2017.00210","DOI":"10.3389\/fonc.2017.00210"},{"key":"852_CR7","doi-asserted-by":"publisher","unstructured":"Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.003.","DOI":"10.1016\/j.radonc.2020.04.003"},{"key":"852_CR8","doi-asserted-by":"publisher","unstructured":"Fleckenstein J, Petroff A, Sch\u00e4fers HJ, Wehler T, Sch\u00f6pe J, R\u00fcbe C. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer. BMC Cancer. 2016;16(1). https:\/\/doi.org\/10.1186\/s12885-016-2379-x.","DOI":"10.1186\/s12885-016-2379-x"},{"key":"852_CR9","doi-asserted-by":"publisher","unstructured":"Lardinois D, Weder W, Hany TF, et al. Staging of Non\u2013Small-Cell lung Cancer with integrated Positron-Emission tomography and computed tomography. N Engl J Med. 2003;348(25). https:\/\/doi.org\/10.1056\/nejmoa022136.","DOI":"10.1056\/nejmoa022136"},{"key":"852_CR10","doi-asserted-by":"publisher","unstructured":"Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. J Thorac Cardiovasc Surg. 2004;127(4). https:\/\/doi.org\/10.1016\/j.jtcvs.2003.08.010.","DOI":"10.1016\/j.jtcvs.2003.08.010"},{"key":"852_CR11","doi-asserted-by":"publisher","unstructured":"Krarup MMK, Fischer BM, Christensen TN. (2022) \u2018New PET Tracers: Current Knowledge and Perspectives in Lung Cancer\u2019, Seminars in Nuclear Medicine, vol. 52, no. 6. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.05.002","DOI":"10.1053\/j.semnuclmed.2022.05.002"},{"key":"852_CR12","doi-asserted-by":"publisher","unstructured":"Mori T, Nomori H, Ikeda K, et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules\/masses: comparison with positron emission tomography. J Thorac Oncol. 2008;3(4). https:\/\/doi.org\/10.1097\/JTO.0b013e318168d9ed.","DOI":"10.1097\/JTO.0b013e318168d9ed"},{"key":"852_CR13","doi-asserted-by":"publisher","unstructured":"Nomori H, Mori T, Ikeda K, et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg. 2008;135(4). https:\/\/doi.org\/10.1016\/j.jtcvs.2007.10.035.","DOI":"10.1016\/j.jtcvs.2007.10.035"},{"key":"852_CR14","doi-asserted-by":"publisher","unstructured":"Usuda K, Sagawa M, Motono N, et al. Advantages of diffusion-weighted imaging over positron emission tomography-computed tomography in assessment of hilar and mediastinal lymph node in lung cancer. Ann Surg Oncol. 2013;20(5). https:\/\/doi.org\/10.1245\/s10434-012-2799-z.","DOI":"10.1245\/s10434-012-2799-z"},{"key":"852_CR15","doi-asserted-by":"publisher","unstructured":"Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDGPET\/CT, and bone scintigraphy. J Magn Reson Imaging. 2009;30(2). https:\/\/doi.org\/10.1002\/jmri.21858.","DOI":"10.1002\/jmri.21858"},{"key":"852_CR16","doi-asserted-by":"publisher","unstructured":"Sommer G, Wiese M, Winter L et al. (2012) \u2018Preoperative staging of non-small-cell lung cancer: Comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography\/ computed tomography\u2019, Eur Radiol, vol. 22, no. 12. https:\/\/doi.org\/10.1007\/s00330-012-2542-y","DOI":"10.1007\/s00330-012-2542-y"},{"key":"852_CR17","doi-asserted-by":"publisher","unstructured":"Chin AY, Min Shin K, Soo K, Lee et al. (2008) \u2018Non-small cell lung cancer staging: Efficacy comparison of integrated PET\/CT versus 3.0-T whole-body MR imaging\u2019, Radiology, vol. 248, no. 2. https:\/\/doi.org\/10.1148\/radiol.2482071822","DOI":"10.1148\/radiol.2482071822"},{"key":"852_CR18","doi-asserted-by":"publisher","unstructured":"Machado Medeiros T, Altmayer S, Watte G, et al. 18F-FDG PET\/CT and whole-body MRI diagnostic performance in M staging for non\u2013small cell lung cancer: a systematic review and meta-analysis. Eur Radiol. 2020;30(7). https:\/\/doi.org\/10.1007\/s00330-020-06703-1.","DOI":"10.1007\/s00330-020-06703-1"},{"key":"852_CR19","doi-asserted-by":"publisher","unstructured":"Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG. Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol. 2015;17(1). https:\/\/doi.org\/10.1093\/neuonc\/nou099.","DOI":"10.1093\/neuonc\/nou099"},{"key":"852_CR20","doi-asserted-by":"publisher","unstructured":"Kr\u00fcger S, Mottaghy FM, Buck AK et al. (2011) \u2018Brain metastasis in lung cancer: Comparison of cerebral MRI and18F-FDG-PET\/CT for diagnosis in the initial staging\u2019, NuklearMedizin, vol. 50, no. 3. https:\/\/doi.org\/10.3413\/Nukmed-0338-10-07","DOI":"10.3413\/Nukmed-0338-10-07"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00852-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00852-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00852-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T10:27:24Z","timestamp":1741861644000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00852-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00852-6","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board approval was obtained (Dnr 216\/326) from the Swedish Ethical Review Authority.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}